%D8%A5%D8%B1%D9%8A%D8%AB%D8%B1%D9%88%D8%A8%D9%88%D9%8A%D8%AA%D9%8A%D9%86Eritropoyetina%E0%A6%8F%E0%A6%B0%E0%A6%BF%E0%A6%A5%E0%A7%8D%E0%A6%B0%E0%A7%8B%E0%A6%AA%E0%A7%8B%E0%A6%AF%E0%A6%BC%E0%A7%87%E0%A6%9F%E0%A6%BF%E0%A6%A8EritropoietinEritropoetinEritropoetinaErythropoetinEPOEpoErythropoetin%DE%87%DE%A8%DE%83%DE%A8%DE%8C%DE%B0%DE%83%DE%AF_%DE%95%DE%AE%DE%87%DE%A8%DE%87%DE%A8%DE%93%DE%A8%DE%82%DE%B0%CE%95%CF%81%CF%85%CE%B8%CF%81%CE%BF%CF%80%CE%BF%CE%B9%CE%B7%CF%84%CE%AF%CE%BD%CE%B7ErythropoietinEritropoetinoEritropoyetinaEr%C3%BCtropoetiinEritropoietina%D8%A7%D8%B1%DB%8C%D8%AA%D8%B1%D9%88%D9%BE%D9%88%D8%A6%DB%8C%D8%AA%DB%8C%D9%86Erytropoietiini%C3%89rythropo%C3%AF%C3%A9tineEiritreap%C3%B3%C3%A9itinEritropoetina%D7%90%D7%A8%D7%99%D7%AA%D7%A8%D7%95%D7%A4%D7%95%D7%99%D7%90%D7%98%D7%99%D7%9FEritropoetin%D4%B7%D6%80%D5%AB%D5%A9%D6%80%D5%B8%D5%BA%D5%B8%D5%A5%D5%BF%D5%AB%D5%B6EritropoietinEritropoietina%E3%82%A8%E3%83%AA%E3%82%B9%E3%83%AD%E3%83%9D%E3%82%A8%E3%83%81%E3%83%B3%EC%97%90%EB%A6%AC%ED%8A%B8%EB%A1%9C%ED%8F%AC%EC%9D%B4%EC%97%90%ED%8B%B4ErythropoietinumEritropoetinasEritropoet%C4%ABns%D0%95%D1%80%D0%B8%D1%82%D1%80%D0%BE%D0%BF%D0%BE%D0%B5%D1%82%D0%B8%D0%BD%E0%B4%8E%E0%B4%B1%E0%B4%BF%E0%B4%A4%E0%B5%8D%E0%B4%B0%E0%B5%8B%E0%B4%AA%E0%B5%8B%E0%B4%AF%E0%B4%B1%E0%B5%8D%E0%B4%B1%E0%B4%BF%E0%B5%BBErytropo%C3%ABtineErytropoietinErytropoetynaEritropoietinaEritropoietin%C4%83%D0%AD%D1%80%D0%B8%D1%82%D1%80%D0%BE%D0%BF%D0%BE%D1%8D%D1%82%D0%B8%D0%BD
about
P688
Granulocyte colony-stimulating factor activating HIF-1alpha acts synergistically with erythropoietin to promote tissue plasticityErythropoietin enhances hippocampal long-term potentiation and memoryRecombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysisSubcutaneous versus intravenous erythropoietin for long-term dialysis patientsEarly versus delayed erythropoietin for the anaemia of end-stage kidney diseaseEarly versus delayed erythropoietin for the anaemia of end-stage kidney diseaseEarly erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsLate erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsEarly versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsInterventions for erythropoietin-resistant anaemia in dialysis patientsSubcutaneous versus intravenous erythropoietin for long-term dialysis patientsLate erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsEarly erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsColony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for strokeErythropoietin or darbepoetin for patients with cancerErythropoietin for minimising perioperative allogeneic blood transfusion in cardiac surgeryErythropoietin for preterm infants with hypoxic ischaemic encephalopathyErythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancerErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataErythropoietin for term and late preterm infants with hypoxic ischemic encephalopathyInterventions for erythropoietin-resistant anaemia in dialysis patientsErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataInterventions for erythropoietin-resistant anaemia in dialysis patientsHaemopoietic growth factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for strokeEarly versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsColony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for strokeColony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for strokeLate erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsEarly erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsErythropoietin for patients with malignant diseaseErythropoietin or Darbepoetin for patients with cancerErythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancerRecombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patientsFrequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patientsErythropoietin for patients with malignant diseaseEarly erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsEarly versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsLate administration of erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infantsA nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activationProtein tyrosine phosphatase 1B participates in the down-regulation of erythropoietin receptor signalling
P921
Q21136403-ECEB292C-1E72-4629-B4B3-DF6E9ABB2BC7Q21245342-60BFA17E-EDC0-43F8-B932-893EAF45F461Q24186430-80E80621-7B29-4331-859E-621766172DA3Q24187032-ACCA05B8-83E6-486D-B75C-C14A958D8FEDQ24187089-7BD9FFA7-BC84-4F87-82F1-923F9167404BQ24194838-166DC118-76E5-4E17-A55F-02E9A13E82E5Q24195000-80F86C17-9239-4BD6-85B9-E398919DFECEQ24195008-2F5766BC-8AF4-4908-B736-4C727243278DQ24197981-BE90B9BE-93A0-4E08-BCE8-7E7BA008BAFBQ24200248-8C221914-5623-4015-A5D1-5B47FB22CC32Q24200417-3A7B870C-4775-4CFF-8DCB-03E214A8C047Q24200513-89115F46-1871-455C-B4FE-53008D07D0FDQ24200642-0A656EA9-D7B0-43DC-91C0-0A724E03105AQ24201855-A2C5EE7E-7D3B-4BE4-A897-42DA93A5F04FQ24202335-25D3AF01-6E77-49DF-B91A-D4F619C21203Q24202404-8DB7EC2E-180B-4624-A0D9-C7BEFF405D50Q24202635-E4F4ABE1-2806-46F2-9092-B1E77D0C4E2BQ24239953-A003D589-BEB7-45D3-A2FD-27E07A4FD2B5Q24240202-1CC763F2-6209-4596-9336-9D5FFB421022Q24241152-4C6C47CD-8E89-464A-A6B0-39EFB7999A33Q24241704-A03C5C92-5646-47D2-9C15-197065BEBAA7Q24242864-294447E1-4016-4D8F-AD34-59E5E56EC4BBQ24243229-87769CFC-440B-488D-B238-A2BA8EA57FBFQ24244557-47BE45C2-6932-4A5C-B48E-425DE0DD0D51Q24245091-FD25555B-B917-4627-BEB3-DE35521C7D01Q24245166-F3BE4CD0-FDAC-478F-B0FD-426A52A69D82Q24245243-17659B6B-14C9-4ADD-9B17-F38C291A5980Q24245263-4713CD05-0CE0-4A6F-B344-A273832A8447Q24245418-238F5552-4189-4594-9F21-1F48CF25AC8DQ24245427-D44F87A4-6D3F-4FFB-8B6E-1F7048BC82CCQ24245464-8D07BECE-F110-4537-8075-81A8849B6CAEQ24245898-C82A683A-B1BA-49D9-9D5C-33066D116CB6Q24246372-0A09D914-CD7E-4C63-8F49-F15C5B9C1D15Q24246665-CC1B49AB-97AC-4E8A-8677-7FF70B4E0831Q24246683-F5BF8245-6769-4CC0-A907-31BB8D07B071Q24246899-79F8A377-A30F-4062-A2BE-2B59C8A2E164Q24246979-BED8423F-878E-407D-A7D2-03A8DABE9F16Q24247008-C76B3C18-EB92-45C1-AC98-0AFD14B45257Q24294741-31D1F83A-7243-4758-BD0C-A7A43C48E24DQ24296932-A90FE809-B6A3-4D9E-9373-3D70D6C1F563
P921
description
chemische Verbindung
@de
chemische stof
@nl
composé chimique
@fr
mammalian protein found in Homo sapiens
@en
protein
@id
protein
@sv
proteinë
@sq
protèin
@ace
بروتين في إنسان عاقل
@ar
name
EPO
@cy
Eiritreapóéitin
@ga
Epo
@da
Eritropoetin
@bs
Eritropoetin
@hu
Eritropoetin
@sl
Eritropoetin
@tr
Eritropoetina
@ca
Eritropoetinas
@lt
Eritropoetino
@eo
type
label
EPO
@cy
Eiritreapóéitin
@ga
Epo
@da
Eritropoetin
@bs
Eritropoetin
@hu
Eritropoetin
@sl
Eritropoetin
@tr
Eritropoetina
@ca
Eritropoetinas
@lt
Eritropoetino
@eo
altLabel
113427-24-0
@fr
122312-54-3
@fr
130455-76-4
@fr
C809H1301N229O240S5
@fr
Czynnik erytropoetyczny
@pl
Darbepoetin
@de
Darbepoietin
@de
DynEpo
@de
EPO
@ar
EPO
@br
prefLabel
EPO
@cy
Eiritreapóéitin
@ga
Epo
@da
Eritropoetin
@bs
Eritropoetin
@hu
Eritropoetin
@sl
Eritropoetin
@tr
Eritropoetina
@ca
Eritropoetinas
@lt
Eritropoetino
@eo
P527
P638
P672
P680
P681
P682
P227
P349
P352
P486
P6366
P637
P646
P672
P1296
P227
P2888
P31
P3471
P349
P352
P373
Erythropoietin